Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients

Clinical Pharmacokinetics

Volumn 45, Issue 9, 2006, Pages 905-922

  Saint Marcoux, Franck ^a   Marquet, Pierre ^a   Jacqz Aigrain, Evelyne ^b   Bernard, Nicole ^c   Thiry, Philippe ^d   Yann, Le Meur ^a   Rousseau, Annick ^a,e,f  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c FOCH HOSPITAL   (France)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY OF LIMOGES   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROEMULSION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; EMULSIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748087118     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645090-00003     Document Type: Article

References (53)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-95
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-33
3. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24 (6): 472-95
4. Keown P, Kahan BD, Johnston A, et al. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies. Report from the International Neoral® TDM Advisory Consensus meeting; 1997 Nov; Vancouver. Transplant Proc 1998; 30: 1465-49
5. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330-50
6. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11 (3): 246-8
7. Parke J, Charles BG. NONMEM population pharmacokinetic modelling of orally administered cylosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit 1998; 20 (3): 284-93
8. Parke J, Charles BG. Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 2000; 56 (6-7): 481-7
9. Rosenbaum SE, Baheti G, Trull AK, et al. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 2005; 27: 116-22
10. Charpiat B, Falconi I, Breant V, et al. A population pharmacokinetic model of cyclosporine in the first postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit 1998; 20 (2): 158-64
11. Breant V, Charpiat B, Sab JM, et al. How many patients and blood levels are necessary for population pharmacokinetic analysis? A study with a one compartment model applied to cyclosporine. Eur J Clin Pharmacol 1996; 51: 283-8
12. Schadeli F, Marti HP, Frey FJ, et al. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet 2002; 41 (1): 59-69
13. Tokui K, Kimata T, Uchida K, et al. Dose adjustment strategy for oral microemulsion formula of cyclosporine: population pharmacokinetics-based analyse in kidney transplant patients. Ther Drug Monit 2004; 26 (3): 287-94
14. Rousseau A, Léger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 2004; 26: 23-30
15. Hesselink DA, Van Gelder T, Van Shaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76 (6): 545-56
16. Kyhl LE, Rasmussen SN, Aarons L, et al. Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart-lung transplanted patients. Transplant Proc 1998; 30 (5): 1680
17. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000; 38 (5): 427-47
18. Kahan BD, Kramer WG, Williams C, et al. Application of Bayesian forecasting to predict appropriate cyclosporine dosing regimens for renal allograft patients. Transplant Proc 1986; 6: 200-3
19. Anderson JE, Munday AS, Kelman AW, et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients. Ther Drug Monit 1994; 16: 160-5
20. Léger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002; 41 (1): 71-80
21. Cremers SC, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003; 18: 1201-8
22. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40: 375-82
23. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant patients over the first year post-transplantation. Eur J Clin Pharmacol 2003; 58 (12): 813-20
24. Akhlaghi F, MacLachlan AJ, Keogh AM, et al. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44: 537-42
25. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003; 25 (1): 28-35
26. Cooney GF, Jeevanandam V, Choudhury S, et al. Comparative bioavailability of neoral and sandimmune in cardiac transplant recipients over 1 year. Transplant Proc 1998; 30: 1892-4
27. Knoop C, Vervier I, Thiry P, et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003; 76 (4): 683-8
28. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM user's guide: introductory guide. Technical Report of the Division of Clinical Pharmacology, University of California. San Francisco (CA): University of California, 1992
29. Gomeni R. Visual-NM user's manual. Research development population pharmacokinetics: graphical interface to NONMEM population data modeling software [online]. Available from URL: http://members.aol.com/rdppweb/vnm_htm. [Accessed 2006 Aug 17]
30. Karlsson MO, Sheiner LB. The importance of modelling inter-occasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21 (6): 735-50
31. Karlsson MO, Beal SL, Sheiner LB. Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm 1995; 23: 651-72
32. Maitre PO, Buhrer M, Thomson D, et al. A three-step approach combining bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377-84
33. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models: models for co-variates effects. J Pharmacokinet Biopharm 1992; 20: 511-28
34. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise co-variate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4 (4): E27
35. Jonsson EN, Karlsson MO. Automated co-variate model building within NONMEM. Pharm Res 1998; 15: 1463-8
36. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003; 56 (2): 205-13
37. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12
38. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software [online]. Available from URL: http://bmsr.usc.edu/Software/ Adapt/usergde.html [Accessed 2006 Aug 17]
39. International Cyclosporin Proficiency Testing Scheme [online]. Available from URL: http://www.bioanalytics.co.uk [Accessed 2005 Dec 15]
40. Holt DW, Denny K, Lee T, et al. Cyclosporin measurement: who cares about inaccuracy? Accred Qual Assur 2001; 6: 405-8
41. Johnston A, Chusney G, Schütz E, et al. Monitoring cyclosporin in blood: between assay differences at through and 2 hours post-dose (C2). Ther Drug Monit 2003; 25 (2): 167-73
42. Morris RG. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring. Ther Drug Monit 2000; 22 (2): 160-2
43. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119-25
44. Friberg LE, Freijs A, Sandstrom M, et al. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 2000; 295 (2): 734-40
45. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-56
46. Felipe CR, Silva Jr HT, Machado PG, et al. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. Transpl Int 2003; 16 (7): 494-503
47. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 1998; 54 (3): 938-44
48. Trull AK, Steel LA, Sharples LD, et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Ther Drug Monit 1999; 21: 17-26
49. Tan KK, Trull AK, Hue KL, et al. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmerger's syndrome. Clin Pharmacol Ther 1993; 53 (5): 544-54
50. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80
51. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75 (5): 422-33
52. Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport. Pharm Res 2002; 19 (4): 457-62
53. Guidance for industry on population pharmacokinetics. US Department of Health services: food and drug administration [online]. Available from URL: http://www.fda.gov [Accessed 2005 Oct 12]